Jupiter Neurosciences, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a JUNS research report →
Price Chart
About the company
Jupiter Neurosciences, Inc. is a pharmaceutical company engaged in clinical-stage research and development. Its primary focus is on advancing a resveratrol-based platform product, with the main objective of addressing neuro-inflammation.
- CEO
- Christer Rosen
- IPO
- 2024
- Employees
- 5
- HQ
- Jupiter, FL, US
Get TickerSpark's AI analysis on JUNS
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.34M
- P/E
- -0.14
- Fwd P/E
- 0.62
- PEG
- 0.00
- P/S
- 20.75
- P/B
- -4.22
- EV/EBITDA
- -0.17
- Div Yield
- 0.00%
- Gross Margin
- 88.34%
- Op Margin
- -15166.68%
- Net Margin
- -14220.12%
- ROE
- 747.33%
- ROIC
- -709.40%
Latest fiscal year · YoY change
- Revenue
- $21.80K+0.0%
- Gross Profit
- $17.57K+0.0%
- Op Income
- $-8,908,721
- Net Income
- $-8,644,897-254.4%
- EPS
- $-18.75-194.8%
- OCF Growth
- -38.4%
- FCF Growth
- -38.4%
- 52W High
- $135.75
- 52W Low
- $2.25
- 50D MA
- $4.11
- 200D MA
- $26.57
- Beta
- 1.88
- RSI (14)
- 39
- Avg Volume
- 983.10K
No earnings-call transcripts are available for JUNS yet.
- Free Float
- 45.6%
- Shares Outstanding
- 484.67K
- Float Shares
- 221.24K
of shares held by institutions
10 13F filers
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Jane Street Group, LLC | 533.39K | ▲ 533.39K |
| Vanguard Group Inc | 248.93K | ▲ 33.10K |
| Virtu Financial LLC | 231.24K | ▲ 217.66K |
| Geode Capital Management, LLC | 156.13K | ▼ 55.57K |
| Vanguard Capital Management LLC | 128.04K | ▼ 231.87K |
| Vanguard Fiduciary Trust Co | 84.17K | ▼ 3.62K |
| Xtx Topco Ltd | 32.77K | ▲ 32.77K |
| Tower Research Capital LLC (Trc) | 28.79K | ▲ 28.79K |
| Northern Trust Corp | 25.35K | 0 |
| Stonex Group Inc. | 20.60K | ▲ 20.60K |
| Level Four Advisory Services, LLC | 10.00K | ▲ 10.00K |
| Vestor Capital, LLC | 2.19K | ▼ 968.79K |
Held by 6 ETFs
Biggest fund positions in JUNS by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 31, 26 | Cutler Andrew Jon | other | 472,222 |
| Jul 22, 26 | Cutler Andrew Jon | other | 0 |
| Jun 2, 25 | Kampf Julie B. | other | 82,875 |
| Jun 2, 25 | Kampf Julie B. | other | 82,875 |
| Jun 2, 25 | Rosen Alexander Gustaf Erik | other | 96,608 |
| Jun 2, 25 | Rosen Alexander Gustaf Erik | other | 164,553 |
| Jun 2, 25 | Rosen Alexander Gustaf Erik | other | 164,554 |
| Jun 2, 25 | Rosen Alexander Gustaf Erik | other | 96,608 |
| Mar 2, 26 | Hayward Marshall A. | other | 225,000 |
| Jun 2, 25 | Hayward Marshall A. | other | 399,402 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our JUNS coverage
Recent articles, reports, and earnings notes.
No research on JUNS yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate JUNS report →Jupiter Neurosciences Announces First Patient Dosed in Phase 2a RESET Trial in Parkinson's Disease and Exploration of Strategic Options to Maximize Shareholder Value
globenewswire.com · Oct 6
Jupiter Neurosciences announces pricing of $2M registered direct offering
https://thefly.com · Aug 21
Jupiter Neurosciences Announces Pricing of $2.0 Million Registered Direct Offering
globenewswire.com · Aug 21
Jupiter Neurosciences Stock Surges Friday: What's Driving the Action?
benzinga.com · Aug 21
Jupiter Neurosciences, Inc. Announces Reverse Stock Split
globenewswire.com · Aug 5
Jupiter Neurosciences (NASDAQ: JUNS) Signs Definitive Agreement for Exclusive U.S. Rights to ALA-002 in Transaction Valued at Up to $100 Million
globenewswire.com · Jul 21
Jupiter Neurosciences Strengthens Board with Appointment of Dr. Tomas J. Philipson
globenewswire.com · Jul 7
Jupiter Neurosciences Announces Patient Enrollment Underway in Phase 2a RESET Trial in Parkinson's Disease
globenewswire.com · May 27
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.